ArticleNPJ breast cancer2026
Outcomes of a prospective cohort study of PREoperative therapy and supportive care in early & locally advanced breast cancers-PreSCella study.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
The PREoperative therapy and Supportive Care in EarLy and Locally Advanced breast cancers (PreSCella) study, conducted within Singapore's SingHealth network, explored how quality of life (QOL) and supportive care needs change over the course of neoadjuvant therapy (NAT) for breast cancer. Using a longitudinal design, data were collected at three points: before NAT (T1), within two months post-surgery (T2), and at the one-year follow-up (T3). Of 241 patients enrolled, 235 were analysed. Overall QOL improved over time, especially emotional well-being. FACT-B scores rose from 113.3 at T1 to 114.3 at T2 and 120.6 at T3 (T1-T3 change: +7.3 points; 95% CI 4.7-9.8; effect size 0.47). Age-specific assessment tools were used. Women under 40 completed three additional surveys-Body Image Scale (BIS), Dyadic Assessment Scale (DAS), and Female Sexual Function Index (FSFI). They reported mild body image distress (BIS: 6.3 at T1 to 7.2 at T3), stable relationships (DAS: 16.5 to 17.0), but notable declines in sexual function (13% at T1, 75% at T2, 57% at T3). Patients over 65 completed tools like the Attitude Scale and prioritised QOL over survival length. Findings underscore the evolving nature of supportive care needs and the value of age-personalised interventions throughout cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.